Condition
Hemostatic Disorders
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 4 (1)
Trial Status
Recruiting2
Terminated1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07075185Phase 1Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT06271252Phase 1Recruiting
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
NCT02281240UnknownPrimary
Hemostatic Complications in Hematopoietic Stem Cell Transplantation
NCT01919840Phase 4TerminatedPrimary
Blood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol
Showing all 4 trials